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Introduction
Helicobacter pylori is a highly prevalent Gram-negative
microaerophilic bacterium. It causes chronic gastric infection
leading to gastritis, peptic ulcer and eventually gastric
cancer.1–3 H. pylori infection is associated with remodelling of
gastric mucosal nerves4 and stimulation of mast cells.5,6 In
animal models, H. pylori infection increases the neural
responsiveness of smooth muscle.7
Virulence markers of H. pylori cytotoxin associated gene
(cagA) and vacuolating cytotoxin gene (vacA) are associated
with different gastroduodenal diseases.8,9 Most H. pylori
strains secrete a VacA cytotoxin that causes structural and
functional alterations in epithelial cells and play an
important role in the pathogenesis of H. pylori-associated
gastroduodenal diseases. 
Mutation of a hydrophobic region near the VacA amino
terminus produces a mutant toxin that fails to induce cell
vacuolation with defective functional activity.10 VacA forms
anion-selective channels in artificial planar lipid bilayers that
increase the anion permeability of the HeLa cell plasma
membrane and determines membrane depolarisation.11
When added to cultured cells, VacA induces vacuolation,
an effect potentiated by pre-exposure of the toxin to low pH.
The anion-selective, voltage-dependent pores formed in
artificial membranes are potentiated by acidic conditions.12
Pore formation is required both for cell vacuolation and
increase of transepithelial conductivity.12
Purified pH-activated VacA, when added to Caco-2 cell
monolayers, demonstrates enterotoxic effect.13 This is time-
and dose-dependent and is saturable.13 Although VacA is
produced by H. pylori in the stomach, it may exert an effect
on more distal regions of the intestine. In gastric and small
bowel epithelia, VacA is known to produce acidic ballooning
of the endoplasmic reticulum and permeabilisation of the
cell membrane, independent of the cytopathic effects.14
In children with diarrhoea, a cytotoxin-inducing
vacuolation in HEp-2 cells was detected in 19 out of 618 stool
specimens, and these resembled those induced by the vacA
of H. pylori.15
The prevalence of H. pylori seropositivity in the authors’
local population in children aged 11–15 years is 53.5%.16
In another study where H. pylori infection was established
by rapid urease test and histopathology, cagA-negative 
H. pylori infection was present in the majority of non-ulcer
dyspepsia patients; however, cagA was associated with
peptic ulcer and gastric carcinoma.17 vacA alleles s1am1 and
s1bm1 are associated with H. pylori-associated disease and
inflammation.17
The aim of the present study is to determine the
distribution of the H. pylori virulence markers cagA and vacA
in irritable bowel syndrome with diarrhoea (IBS-D)
according to the Rome III criteria, compared to the
distribution in patients with chronic diarrhoea. 
Materials and methods
A total of 330 patients were enrolled in the study, comprising
170 (52%) with IBS-D and 160 (48%) with chronic diarrhoea.
Mean age of the IBS-D group was 41±15 years (range: 16–83;
males: 116, females: 54). Mean age of the 160 patients with
chronic diarrhoea used as controls was 42±14 years (range
15–75; males: 106, females: 54). Patients in the control group
had abdominal pain or discomfort associated with
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intermittent diarrhoea that did not fulfill the Rome III
criteria for IBS-D. 
Patients meeting the Rome III criteria for IBS-D had
symptoms for at least three months, with onset at least six
months previously.18 These patients underwent thorough
history, physical examination, complete blood count, serum
creatinine, electrolytes, stool microscopy, oesophago-
gastroduodenoscopy (EGD) and colonoscopy. On EGD,
gastric and duodenal biopsies were taken for H. pylori
infection, coeliac disease and giardiasis. On colonoscopy,
rectal biopsy was taken for the diagnosis of inflammatory
bowel disease, microscopic colitis and infective colitis. They
also had serology for tissue transglutaminase (TTG) IgA and
IgG antibodies for coeliac disease. 
Gastric biopsy specimens were used for histopathology for
the diagnosis of H. pylori and DNA extraction for the
polymerase chain reaction (PCR) to amplify H. pylori genes
for ribosomal DNA (rDNA), cagA and vacA alleles s1 and s2.
Gastritis was graded on a four-point scale of none (grade
0), mild (grade 1), moderate (grade 2), and severe (grade 3)
according to the Sydney guidelines.19 The presence of
H. pylori was assessed on haematoxylin and eosin (H&E)-
stained sections. Diagnosis of H. pylori infection was
established when PCR for 16S rDNA or a specific PCR for 
H. pylori was positive. 
Exclusion criteria included previous history of peptic ulcer
disease, history of treatment for H. pylori, concurrent or
recent antibiotic use (e.g., metronidazole, clarithromycin,
amoxicillin, tetracycline, doxycycline and other
cephalosporins), histamine-2 receptor blocker or proton
pump inhibitor therapy, and concurrent infection with
Blastocystis hominis or Giardia lamblia.
The study was approved by the institutional ethics review
committee. 
Faecal smear microscopy 
Briefly, approximately 2 mg faeces was emulsified on a glass
slide in one drop of physiological saline and covered with a
cover slip. A similar preparation was made on another slide
using Lugol’s iodine. These preparations were examined
under low power (x10) and high power (x40) objective
lenses. 
Extraction of genomic DNA
The extraction of DNA was performed as described
previously.20 Briefly, gastric tissue was homogenised in 
500 µL sterile water and centrifuged at 12,000 xg for 3 min.
Then, 500 µL lysis buffer (100 mmol/L NaCl, 10 mmol/L 
Tris-HCl [pH 8.0], 25 mmol/L EDTA, 0.5% sodium dodecyl
sulphate) and 10 µL proteinase K (10 mg/mL) were added.
Incubation was carried out at 50˚C for 20 h, followed by
phenol-chloroform extraction and ethanol precipitation. 
The resulting pellet was allowed to dissolve in 40 µL TE
buffer (10 mmol/L Tris-HCl [pH 7.4], 0.1 mmol/L EDTA 
[pH 8.0]) for 20 h at 37˚C. Samples were stored at –20˚C
prior to PCR amplification. The DNA content and purity
were determined by measuring the absorbance at 260 nm
and 280 nm, respectively, using a spectrophotometer
(Beckman DU-600, USA). 
PCR amplification 
The PCR reaction was performed using extracted DNA as the
template. Samples that were positive for Helicobacter genus
16S rDNA were subsequently analysed with different
primers to detect the cagA, cagA empty site and vacA alleles
(e.g., s1 and s2) (Table 1) which encode potential virulence
factors in H. pylori.21,22 If cagA was negative, PCR was
performed to confirm the presence of cagA empty site in
cagA-negative strains, and to eliminate cases of amplification
failure. Primers used were those described previously.23,24
Amplification was carried out in a total volume of 50 mL
containing 2 mL 2 mmol dNTPs, 1 mL 50 pmol each forward
and reverse primer25,26 (synthesised by MWG automatic
synthesiser), 1 unit Thermus aquaticus (Taq) DNA polymerase
(Promega), 5 µL 10x PCR reaction buffer, 3 mmol/L MgCl2
and 2 mL DNA template containing 0.5 ng extracted DNA.
Total volume was increased to 50 µL by the addition of
double-distilled water. The reaction was carried out in a
Perkin Elmer 9700 thermal cycler, and the amplification
cycles for the various H. pylori genes are shown in Table 1. 
Region amplified Primer Primer sequences (5’→3’) PCR PCR cycles
designation product 
(bp)
16S rRNA21 C97 GCT ATG ACG GGT ATC C 400 94˚C for 5 min, 94˚C for 1 min,
55˚C for 1 min, 72˚C for 90 sec 
C 98 GAT TTT ACC CCT ACA CCA (35 cycles), 72˚C for 7 min
vacA alleles22 S1 ATGGAAATACAACAAACACAC 25919 One cycle of 95˚C for 5 min, 
35 cycles of 95˚C for 1 min, 
S2 CTGCTTGAATGCGCCAAAC 28619 52˚C for 1 min, 72˚C for 1 min,
and one cycle of 72˚C for 5 min
cagA23 D008 GGTCAAAATGCGGTCATGG 29719 One cycle of 94˚C for 5 min, 
35 cycles of 94˚C for 1 min, 
R008 TTAGAATAATCAACAAACATCACGCCAT 55˚C for 1 min, 72˚C for  1 min, 
and one cycle of 72˚C for 5 min
Empty site24 ES-F ACATTTTGGCTAAATAAACGCTG 360 One cycle of 94˚C for 5 min, 
40 cycles of 94˚C for 1 min, 
ES-R TCATGCGAGCGGCGATGTG 55˚C for 1 min, 72˚C for 1 min, 
and one cycle of 72˚C for 5 min
Table 1. Oligonucleotide primers used in typing H. pylori genes.
Positive and negative control reactions were performed
with each batch of amplifications. DNA from H. pylori strains
ATCC 43504 (vacAs1am1, cagA-positive), ATCC 51932 
(vacA s2m2, cagA-negative) and ATCC 43526 (vacA s1bm1,
cagA-positive) was used to define the accuracy of the cagA
and vacA alleles. After PCR, the amplified products were
electrophoresed in 2% agarose gels containing 0.5%
Tris/acetate/ethylenediaminetetraacetic acid, stained with
ethidium bromide, and visualised under an ultraviolet (UV)
light source.
Sample size 
Using NCSS (PASS) software for the sample size calculation,
a group of 330 subjects was required to achieve 80% power
to detect a difference of 15% that prevalence of H. pylori in
IBS patient would be 69% when compared to the non-IBS
group16,25 at a 5% level of significance.
Statistical analysis
Results were expressed as mean+standard deviation (SD)
for continuous variables (e.g., age) and number (percentage)
for categorical data (e.g., gender, stool culture, diarrhoea).
Univariate analysis was performed using the independent
sample t-test, Pearson χ2 test and Fisher Exact test where
appropriate. P<0.05 was considered statistically significant.
All P values were two sided. Statistical interpretation of data
was performed using SPSS version 16.0.
Results
On EGD, H. pylori gastritis was present in 162 (49%) patients
and non-specific gastritis was present in 168 (51%). 
At colonoscopy, 138 (42%) had non-specific inflammation
while 192 (58%) were reported as normal (Table 2). 
On histopathology, gastric biopsy revealed chronic active
gastritis in 90 (53%) and chronic gastritis in 80 (47%) patients
with IBS-D compared to 63 (39%) and 97 (61%), respectively,
in patients with chronic diarrhoea (P=0.02). Colonic biopsies
revealed non-specific inflammation in 90 (53%) and normal
colonic mucosa in 80 (47%) in patients with IBS-D compared
to 102 (64%) and 58 (36%), respectively, in patients with
chronic diarrhoea (P=0.05) (Table 2).
Prevalence of infection 
H. pylori was positive in 116 (68%) with IBS-D compared 
to 88 (55%) in the control group (P=0.01). It was associated
with H. pylori-positive gastritis in 91 (54%) patients with 
IBS-D compared to 71 (44%) in the control group (P=0.09)
(Table 2).
Distribution of virulence markers
cagA was positive in 115 (56%), cagA empty site in 89 (44%),
vacAs1 in 93 (46%), vacAs2 in 124 (61%), cagAs1 in 53 (26%)
and cagAs2 in 68 (33%) (Figs. 2 and 3). cagA was positive in 
73 (63%) patients with IBS-D compared to 42 (48%) in the
control group (P=0.03) (Table 2). H. pylori infection with 
cagA empty site was positive in 43 (37%) in patients with 
IBS-D and 46 (52%) in the control group (P=0.03). vacAs1
was positive in 61 (53%) patients with IBS-D compared to 
32 (36%) in the control group (P=0.02) (Table 2). cagAs1 was
positive in 39 (34%) patients with IBS-D compared to 
13 (15%) in the control group (P=0.002) (Table 2). 
Comparison of infection in different groups
No age- or gender-related differences in H. pylori positivity
were seen, nor differences in H. pylori-associated gastritis in
the two groups (Tables 2 and 3). cagA was positive in 
73 (63%) patients with IBS-D compared to 42 (48%) in the
control group (P=0.03), while vacAs1 was positive in 
61 (53%) with IBS-D compared to 32 (36%) in the control
group (P=0.02) (Table 3). cagAs1 was positive in 39 (34%)
patients with IBS-D compared to 14(16%) in the control
group (P=0.004) (Table 3).
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IBS Controls P value
(n=170) (n=160)
Age
Mean±SD 40±15 42±14
Range 16–83 15–75
Gender
Male 116(69) 106(66)
Female 54(31) 54(34)
EGD
H. pylori-positive gastritis 91(54) 71(44) 0.09
H. pylori-negative gastritis 79(46) 89(56)
Colonoscopy
Normal 80(47) 58(36) 0.05
Non-specific 90(53) 102(64)
PCR for Helicobacter pylori
16S rDNA
Positive 116(68) 88(55) 0.01
Negative 54(43) 72(45)
cagA
Positive 73(63) 42(48) 0.03
Negative 43(37) 46(52)
cagA-empty site
Positive 43(37) 46(52) 0.03
Negative 73(63) 42(48)
vacAs1
Positive 61(53) 32(36) 0.02
Negative 55(47) 56(64)
vacAs2
Positive 67(58) 57(65) 0.31
Negative 49(42) 31(35)
cagAs1
Positive 39(34) 13(15) 0.002
Negative 77(66) 75(85)
cagAs2
Positive 38(33) 30(34) 0.84
Negative 78(67) 58(66)
Univariate analysis was performed using the independent sample 
t-test; Pearson χ2 test and Fisher Exact test were also used 
where appropriate. P<0.05 was considered statistically significant.
Percentage shown in parentheses.
Table 2. Details of patients enrolled in the study.
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Discussion
The implications of the study reported here are that 
H. pylori infection is associated with H. pylori strains that are
cagAs1-positive, compared to a previously reported
increased incidence of cagA-negative H. pylori strains in
patients with non-ulcer dyspepsia.17 It shows variation in the
distribution of H. pylori virulence markers in IBS-D
compared to non-ulcer dyspepsia.
There is evidence to suggest that H. pylori vacuolating
toxin has a role in causing diarrhoea as it produces
vacuolation in colonic epithelial cells. However, the present
study did not demonstrate this effect, and was only able to
show an increase in distribution of H. pylori virulence
markers in IBS-D patients. 
It is known that that co-infection with parasitic organisms
tends to modulate the immune response;27 however, patients
in the present study did not show evidence of infestation
(e.g., Blastocystis hominis) on stool examination.
Irritable bowel syndrome is a heterogeneous disorder and
not all patients with IBS give a history of gastroenteritis,
pelvic surgery and psychological trauma.26 It is possible 
that H. pylori infection serves to sensitise the bowel and 
leads to the appearance of IBS symptoms.28 The VacA
cytotoxin secreted by H. pylori strains may contribute to
diarrhoea in IBS-D following structural and functional
alterations to intestinal epithelial cells that increase their
permeability.11
In conclusion, the present study showed that H. pylori
infection is common in patients with IBS-D, and is 
associated with virulent strains that are predominantly
cagAs1-positive. However, further studies are required to
illustrate the effect of H. pylori virulence markers in 
patients with IBS. 5
The authors are grateful to the staff of the Juma Research
Laboratory for their help during completion of this work.
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